Publications

2011

• Activation of Ras requires the ERM-dependent link of actin to the plasma membrane.
  Sperka T, Geissler KJ, Merkel U, Scholl I, Rubio I, Herrlich P, Morrison HL
  PLoS One 2011, 6(11), e27511
  
• p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)
  Stefan F, Solveigh C K, Stefan A L
  Expert Opin Ther Pat 2011, 21(12), 1843-66
  

2010

• Regulation of cellular actin architecture by S100A10.
  Jung* MJ, Murzik* U, Wehder L, Hemmerich P, Melle C
  Exp Cell Res 2010, 316(7), 1234-40 * equal contribution
  
• What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.
  Kissil JL, Blakeley JO, Ferner RE, Huson SM, Kalamarides M, Mautner VF, McCormick F, Morrison H, Packer R, Ramesh V, Ratner N, Rauen KA, Stevenson DA, Hunter-Schaedle K, North K
  Am J Med Genet A 2010, 152A(2), 269-83
  
• Merlin inhibits neurite outgrowth in the CNS.
  Schulz A, Geissler KJ, Kumar S, Leichsenring G, Morrison* H, Baader* SL
  J Neurosci 2010, 30(30), 10177-86 * equal contribution
  

2009

• Properties of an ezrin mutant defective in F-actin binding.
  Saleh HS, Merkel U, Geissler KJ, Sperka T, Sechi A, Breithaupt C, Morrison H
  J Mol Biol 2009, 385(4), 1015-31
  

2007

• Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.
  Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P
  Cancer Res 2007, 67(2), 520-7
  
• Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin.
  Orian-Rousseau* V, Morrison* H, Matzke A, Kastilan T, Pace G, Herrlich P, Ponta H
  Mol Biol Cell 2007, 18(1), 76-83 * equal contribution, published during change of institution